Physician profile
Yan Chen
NPI 1184627101
$520.27
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $133 · 2022: $70.95 · 2023: $235 · 2024: $82.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $295 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $294.57 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $163.46 | 2022-2024 | Rinvoq, Skyrizi, Creon |
| Medtronic, INC. | $116.48 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $54.64 | 2022-2023 | Dupixent |
| Janssen Biotech, INC. | $33.79 | 2023 | Stelara |
| Ferring Pharmaceuticals INC. | $31.75 | 2023 | Rebyota |
| Stryker Corporation | $24.53 | 2024 | Neptune |
| Gilead Sciences, INC. | $21.14 | 2023 | |
| Celgene Corporation | $20.69 | 2023 | Zeposia |
| Lilly USA, LLC | $19.57 | 2023 | |
| Braintree Laboratories, INC. | $18.11 | 2024 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $16.11 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,979.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yan Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.